joe...iece is looking better and better...we just have to hope someone notices the progress the company is making.
coz...my last api purchase was at 1.20 and I thought i nailed it.
strictly fwiw...the wsj front page int'l section today was all about mad cow disease and how it is tearning up europe, businesses etc...this out last week..i took a position...do your own dd...
Vitro Files Patent: May Prevent 'Mad Cow Disease' Spread to Biotech Products
LITTLETON, Colo., March 8 /PRNewswire/ -- Vitro Diagnostics, Inc. (OTC Bulletin Board: VODG - news) announced today that it has filed a patent application with the United States Patent and Trademark Office entitled ``Defined Medium for the Culture of Human Cells.''
This filing seeks patent protection for the Company's specially formulated, liquid cell culture medium, which can be used to grow human cells in a manner that ensures their protection against infection by ``Mad Cow Disease.'' Biotechnology scientists often grow their product-producing cells in a medium containing fetal bovine serum. With the ever-increasing spread of ``Mad Cow Disease,'' there is a high demand for media that can guarantee that ``Mad Cow Disease'' would not be spread via therapeutic interventions.
The Company has derived a specialty medium that is optimal for the proliferation of human cells in cell culture. This medium is serum-free and contains clearly defined components that are available from non-animal sources. This medium is necessary for production of biopharmaceutical materials that originate from cultured human cells. Current FDA guidelines suggest the use of defined, serum-free culture medium to produce biological therapeutic products because of concerns regarding the introduction of contamination into drug products.
The Company's product pipeline includes various forms of purified FSH and related products for use in the treatment of infertility. A plan for the approval of its first product, VITROPIN(TM), is under review by the FDA. VITROPIN(TM) is a highly purified form of urinary FSH produced through the Company's patented method. Additional patent-pending products include VITROPIN-C(TM), custom FSH that reduces side effects of current products, VITROPIN-V(TM), a breakthrough FSH product produced from a proprietary immortalized cell line, and VITROJECT(TM), a novel drug injection device for administration of FSH and other drugs.
VITROCELL-X(TM) is the designation of a series of immortalized cell lines in which ``X'' represents the organ from which the cell line was derived, and each of which produces ``natural therapeutic'' products. For example, ``VITROCELL-PG(TM)'' is a cell line derived from the human pituitary gland that produces FSH. VITROCELL-X(TM) cell lines are produced by the Company's proprietary platform technology method, VITROCELL-X(TM) CELL IMMORTALIZATION TECHNOLOGY, which uses the controlled over-expression of specific genes to produce cellular immortalization.
The newly discovered medium that is the subject of the recently filed patent application would be used in the production of ``Naturally Pure Therapeutics''(TM) from immortalized human cells.
Additional information may be accessed through the Company's web site at www.vitrodiag.com.
Certain statements contained herein which are not historical constitute ``forward looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as ``intends,'' ``anticipates,'' ``believes,'' ``expects'' and ``hopes'' and include, without limitation, statements regarding the Company's plan of business operations, development of products or technologies, receipt of revenues, future financings and completion of certain transactions. Factors that could cause actual results to differ materially include, among others set forth in the Form 10-KSB under the caption ``Risk Factors,'' the following: availability of necessary capital to develop its products, acceptability of the Company's product in the market place, general economic conditions, competition and decisions of third parties over which the Company has no control. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Vitro Diagnostics, Inc.
Email this story - Most-emailed articles - Most-viewed articles |
